Vivos Therapeutics (VVOS) Stock
Small healthcare maker of custom sleep apnea devices. Here's the price, business snapshot, and what's worth knowing about Vivos Therapeutics in October 2026.
Vivos Therapeutics Inc (VVOS) is a micro‑cap healthcare company developing and commercialising oral appliance therapies and airway‑centred dental solutions aimed at treating sleep‑disordered breathing, including mild‑to‑moderate sleep apnoea. The company’s model centres on bespoke dental devices designed to expand the upper airway, distributed through a network of trained providers and partner clinics. With a market capitalisation of roughly $20.7 million, VVOS is a small, illiquid stock prone to price volatility; revenues and profitability have been variable as the business invests in clinical validation and market expansion. Key factors for investors include regulatory oversight, reimbursement environments, clinical adoption rates and intellectual property strength. Potential upside exists if clinical acceptance and sales scale, but risks are material and execution dependent. This is general educational information, not personalised investment advice. Values can fall as well as rise; prospective investors should assess suitability for their circumstances and consider professional guidance.
Why You’ll Want to Watch This Stock
Sleep therapy growth
Rising awareness of sleep apnoea and interest in non‑CPAP options could create market opportunity, though clinical adoption and reimbursement will determine impact.
Small‑cap volatility
With a market cap around $20M, shares can be illiquid and volatile; this profile suits investors ready to accept higher risk and potential price swings.
Regulation and adoption
Regulatory approvals, clinical evidence and provider uptake are key growth levers—outcomes here can materially influence future performance.
